What drugs does Elanco make?
Elanco Animal Health manufactures and distributes an extensive portfolio of veterinary pharmaceuticals, vaccines, parasiticides, and nutritional health products designed for companion animals and livestock production. Its popular commercial product lineup features Seresto flea and tick collars, Advantage and Advantus topical parasite treatments, Atopica for canine and feline allergic dermatitis, and Credelio for flea and tick prevention. For livestock producers, Elanco manufactures essential antibiotics, performance enhancers, and vaccines like Nuplura PH and Tylan, ensuring health and disease management for cattle, swine, and poultry globally.
Related FAQs
Elanco Animal Health anticipates an exceptionally strong future growth outlook driven by its momentum-backed, innovation-led strategy.
No, Elanco Animal Health is no longer owned by Eli Lilly and Company. While Elanco was a subsidiary of Eli Lilly for many years, it was officially divested in 2019.
Executive compensation for the chief executive leadership guiding Element Fleet Management Corp. (a leading global automotive fleet management and leasing enterprise) reflects corporate governance benchmarks.
Staff members and retail personnel employed by Clicks Group in South Africa earn wages and salaries structured around store formats, retail experience, and professional pharmacy qualifications.
ELAN (Elanco Animal Health) has been highlighted by some analysts as offering a compelling investment case, particularly for those interested in the niche animal health sector.
Equity research analysts evaluate corporate entities, specialized technology firms, or pharmaceutical enterprises trading under designations like ELAN by analyzing fundamental balance sheet health, revenue compounding, and sector-specific demand driv...
As of July 25, 2026, Elanco Animal Health (ELAN) holds a "Buy" consensus rating from Wall Street analysts. This consensus is based on the aggregate assessments of professional analysts who follow the company.
Linamar Corporation distributes regular quarterly cash dividend payments to its eligible shareholders, operating as a prominent global manufacturing enterprise specializing in precision machined components and industrial systems listed on the Toronto...
No, the most prominent company known as "Elan" is a sporting goods manufacturer headquartered in Begunje na Gorenjskem, Slovenia. It is globally recognized for its production of high-quality skis and snowboards. It is not an American company.
Yes, Elanco Animal Health has demonstrated profitability. In its first-quarter 2026 financial results, the company reported revenue of $1,371 million—a 15% year-over-year increase—and raised its full-year guidance.
No, Elastic N.V. (ESTC), the company behind the popular search and analytics software, does not pay a dividend.
Whether ELAN is a "good buy" depends on an investor's individual financial objectives and risk tolerance, though the stock currently carries a "Buy" consensus rating from analysts as of July 2026.
Elanco Animal Health is viewed by many market participants as a strong candidate for long-term growth within the specialized animal health sector.
No, Elanco Animal Health (ELAN) does not pay a dividend to its shareholders.
Examining the stock volatility of Enova International, Inc.—a technology-driven financial services company providing online lending products to non-prime consumers—shows an exceptionally high-beta, volatile market profile.
Yes, Element Fleet Management has consistently maintained strong profitability, highlighted by multi-year revenue increases and robust net earnings results.
Elan forecasts typically encompass projected financial trajectories, revenue expectations, or product market adoption estimates for corporate entities, medical treatments, or financial funds bearing the Elan name.